Israel Active

Over 500 Jewish doctors and healthcare professionals, including 260 doctors, gathered at the 10th annual MedEx event in Teaneck, New Jersey. The International Medical Aliyah Program (IMAP) started MedEx to bring 2,000 Jewish doctors to Israel. In 2024 alone it brought 519.

Israel’s Enovid (see previously) has now launched its SaNOtize Nitric Oxide Nasal Spray as NOWONDER in the US. NOWONDER delivers advanced nasal cleansing, viral protection (e.g. against COVID-19), and sinus health support.

An Israeli-led research team has analyzed how the brain processes speech and transforms sounds into conversation. It could lead to new advancements in speech recognition technology, tools for people with speech disorders, and personalized assistive devices.

Israel’s Purple Biotech (see previously) has partnered with the Icahn School of Medicine at Mount Sinai New York, to develop CAPTN-3, a platform of activated antibodies. The aim is to enhance tumor-specific immunity against various cancer types.

Israel’s OncoRedox is developing a new platform for the early diagnosis and monitoring of cancer and chronic diseases. Its disposable sensor plus AI-powered technology is designed to detect and profile cell-free metabolites within minutes, providing a unique metabolic fingerprinting.

A discovery by Weizmann scientists has astounded the world of microbiology (and the BBC). Every cell in the human body makes bacteria-killing chemicals to recycle proteins. These natural antibiotics could transform future research into combating resistant bacteria.

Israel’s Sheba Medical Center increased its position from ninth to eighth on Newsweek’s ranking of the best hospitals in the world .  Sourasky (Ichilov) was at 60, and Rabin (Beilinson) was at 122. Hadassah Ein Kerem made the list for the first time coming in at 242.

As part of 2025 National Defibrillator Day, Magen David Adom volunteers set up over 500 training stations across Israel. They showed 35,000 members of the public how to recognize the signs of cardiac arrest, locate and operate a nearby Automated External Defibrillator, and call 101 for assistance.

Israel’s Lutris is developing a topical B-Raf Inhibitor LUT014 - a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to cancer patients without interruptions caused by skin problems.

Nora Nseir is the founder and co-CEO of Nurami Medical (see previously) explains Nurami’s latest groundbreaking product, which is able to to regenerate meningeal tissue after complex brain and spinal cord surgery. Nurami’s first product stops cerebrospinal fluid leakage post-surgery.